newsfilter
← Latest News
ACCESS Newswire·

CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements

SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 23, 2025 / CASI Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class,